trending Market Intelligence /marketintelligence/en/news-insights/trending/ermucopms5paxixmrhhgcg2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Onconova regains compliance with Nasdaq $1 listing requirement

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Onconova regains compliance with Nasdaq $1 listing requirement

Onconova Therapeutics Inc. has regained compliance with Nasdaq's $1 minimum bid price listing rule.

Onconova was notified by Nasdaq in May that it was no longer in compliance with the rule, which requires all trading companies to maintain a stock price of at least $1 for a minimum of 10 consecutive business days. Onconova was given until Nov. 5 to regain compliance.

The Newtown, Pa.-based company implemented a 1-for-15 reverse split of its common stock in September to get back in line with the rule. Onconova stock began trading on a split-adjusted basis as of Sept. 26, and by Oct. 9 had met the 10-day requirement of trading over the $1 bid price.

Onconova develops small molecule product candidates to treat cancer.